ATSUSHI HOSUI | Oncology Pharmaceuticals | Pharmaceutical Excellence Award
Dr. ATSUSHI HOSUI, Osaka Rosai Hospital, Japan
Dr. Atsushi Hosui, a distinguished hepatologist, earned his M.D. from Osaka University in 1994 🎓. With Japanese Medical License #363021, he holds multiple board certifications in internal medicine, gastroenterology, and hepatology 🏥. Currently serving as Director of Hepatology at Osaka Rosai Hospital, he has led and contributed to numerous clinical trials on NASH, MASH, PBC, and liver cancer 🧬. A member of Japan’s leading medical societies, he is also GCP-trained (2015) 📋. Renowned for his impactful research and over 30 scientific publications, Dr. Hosui is a trailblazer in liver disease therapeutics and pharmaceutical excellence.
Publication Profile
Education
Dr. Atsushi Hosui embarked on his medical journey at the prestigious Osaka University, Japan 🗾, where he earned his Doctor of Medicine (M.D.) degree in March 1994 🎓. Renowned for its excellence in medical education and research, Osaka University provided him with a solid foundation in clinical medicine and scientific inquiry 🧪. His education laid the groundwork for a remarkable career in gastroenterology and hepatology 🏥. Driven by a passion for improving liver health, Dr. Hosui has since become a respected physician, researcher, and clinical investigator, dedicated to advancing pharmaceutical science and patient care globally.
Awards
Dr. Atsushi Hosui holds a prestigious Japanese Medical License (#363021) 🇯🇵, validating his long-standing commitment to clinical excellence. He is a board-certified member and specialist of the Japanese Society of Internal Medicine 🧬, where he also serves as an advising doctor 👨⚕️. His specialization extends to gastroenterology and hepatology, holding certified status from the Japanese Society of Gastroenterology 🏥, the Japan Society of Hepatology 🏆, and the Japan Gastroenterological Endoscopy Society 🔬. These recognitions underscore his expertise in digestive health and liver diseases, reflecting a distinguished career devoted to patient care and research innovation.
Experience
Dr. Atsushi Hosui has led and contributed to numerous groundbreaking clinical research projects in hepatology and internal medicine 🧬. As an investigator or sub-investigator, he played key roles in studies on NASH (2021–2022) and MASH (2024–2025) 🩺. His focus on hypozincemia (2015), hepatocellular carcinoma (2012–2016), portal vein thrombosis (2015–2016), and PBC (2025–) highlights his expertise in liver-related conditions 🧠. He also contributed significantly to studies on thrombocytopenia and chronic hepatitis C (2013) 🧫. Dr. Hosui’s research dedication reflects his mission to improve liver health and advance pharmaceutical excellence globally.
Research Focus
Dr. Atsushi Hosui’s research is centered around hepatology and gastroenterology, with a strong emphasis on hepatocellular carcinoma (HCC) 🧫, chronic liver diseases 🏥, and vascular complications like gastric varices and Budd-Chiari syndrome 🫀. His clinical investigations span topics such as portal hypertension, black esophagus, hyperglycemic complications, and the long-term risks of hepatitis B treatments 🦠. His innovative approaches combine locoregional therapies, embolization techniques, and pharmacologic interventions to enhance liver cancer outcomes 🎯. Dr. Hosui’s work bridges diagnostic precision with therapeutic advancements in liver-related pathologies, reinforcing his role as a leader in hepatic disease management.
Publication Top Notes
- Management of Gastric Varices with Portopulmonary Venous Anastomosis: A Combined Approach Using Percutaneous Transhepatic Coil Embolization and Balloon-Occluded Retrograde Transvenous Obliteration
- Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC
- Black Esophagus in Hyperosmolar Hyperglycemic Syndrome
- The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs
- Solitary Cardiac Metastasis of Hepatocellular Carcinoma
- Hepatocellular Carcinoma Associated with Secondary Budd-Chiari Syndrome